Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 211-941-3 | CAS number: 717-74-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The acute oral LD50 is > 2000 mg/kg bw.
The acute inhalation (aerosol) 4h-LC50 is > 5.0 mg/L.
The acute dermal LC50 is >2000 mg/kg bw.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Jan 15 to May 22, 2015
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- 2001
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: Batch No. 6F11027000
- Expiration date of the lot/batch: 17.11.2016
- Purity: 96% - Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, Sandhofer Weg 7, 97633 Sulzfeld, Germany
- Females nulliparous and non-pregnant: Yes
- Age at study initiation: 7-8 wks
- Fasting period before study: 3 hrs
- Housing: In groups of 3 animals in Tecniplast Type 2000P open cages (ca. 10% larger than Eurostandard Type IV cages)
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: At least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3°C
- Humidity (%): 30-70%
- Air changes (per hr): 10 air changes per hour
- Photoperiod (hrs dark / hrs light): 12 h light/12 h dark, artificial lighting - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- VEHICLE
- Amount of vehicle (if gavage): 4 mL/ kg bw per gavage
- Justification for choice of vehicle: As the test item's solubility in water is poor, corn oil was used as an organic solvent. Pre tests showed that the solubility of the test item in corn oil was sufficient.
- Lot/batch no. (if required): Sigma, Catalogue # 1636
- Purity: 100%
CLASS METHOD
- Rationale for the selection of the starting dose: A starting dose of 2000 mg/kg bw was determined based on information from former studies on the test item (single dose LD50 < 5000 mg/kg bw) - Doses:
- Planed: 2000 mg/kg, 300 mg/kg, 50 mg/kg, 5 mg/kg
- No. of animals per sex per dose:
- 6
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: For fatalities: twice within 4h after each application, daily for remainder of observation period thereafter. For clinical signs/behavior: daily. For body weight: once before application, then weekly
- Necropsy of survivors performed: Yes
- Other examinations performed: clinical signs, body weight, organ weights, histopathology, other: clinical signs (behavior) and body weight - Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- All animals survived during the planned in-life period. No animals died during the study.
- Clinical signs:
- other: All animals survived during the planned in-life period. Only one animal (E54/0) showed a slight change of behavior shortly after the application (slight lethargy, piloerection at the head, slight abnormal walk).40 minutes later this change was not detecta
- Gross pathology:
- During necropsy no alterations were found. Only animal ESS/0 of the second run showed a slightly reddened thyroidea.
- Interpretation of results:
- GHS criteria not met
- Remarks:
- according to EC 1278/2008 as amended
- Conclusions:
- Following the administration of a single dose of 2000 mg/kg body weight of the test item in 6 female rats, no animals died during the study and no animals showed severe suffering or moribundity. A slight reversible change of behavior was detected in one animal as well as minor weight loss in another animal. No distinct changes could be noted during necropsy. The LD50 was therefore expected to overlie 2000 mg/kg bodyweight.
- Executive summary:
Following the administration of a single dose of 2000 mg/kg body weight of the test item in 6 female rats, no animals died during the study and no animals showed severe suffering or moribundity. A slight reversible change of behavior was detected in one animal as well as minor weight loss in another animal. No distinct changes could be noted during necropsy. The LD50 was therefore expected to overlie 2000 mg/kg bodyweight.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- The database is robust given the number and type of studies available, and consistency of findings.
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Apr 22 to Jul 16, 2015
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 436 (Acute Inhalation Toxicity: Acute Toxic Class Method)
- Version / remarks:
- Version not specified
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: Eastman Chemical Company, Batch No. 6F11027000
- Expiration date of the lot/batch: 17/11/2016
- Purity: 96% - Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (Barcelona, Spain)
- Females nulliparous and non-pregnant: Yes
- Age at study initiation: 8 wks
- Weight at study initiation: males: ca. 286 - 278 g; females: ca. 212 - 238 g
- Housing: Bedding material: Capsumlab Lecho_10 (autoclavable)
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 8 days (Acclimatisation to the nose-only restraining tubes was performed for 35 minutes immediately before the exposure)
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 16.4-23.7ºC
- Humidity (%): 21-52%
- Photoperiod (hrs dark / hrs light): 12:12, 07.00 to 19.00 CET - Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- nose only
- Vehicle:
- clean air
- Mass median aerodynamic diameter (MMAD):
- 1.7 µm
- Remark on MMAD/GSD:
- Geometric Standard Deviation (GSD) on the two PSD determinations (PSD #1 and PSD #2) were 4.3 and 5.4 respectively, which are above the target range (1.5 to 3). Single outliers during weighing may have contributed to these high values. Nevertheless, these values were considered to be acceptable taking into account that more than 89% and 67% of particles were below upper limit of 4µm in PSD #1 and PSD #2 respectively. Hence, the particle size distributions obtained were considered to be respirable to rats and these incidents are considered to have no impact on the quality / integrity of the study.
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: flow-past, nose-only; Exposure chambers type EC-FPC-232 (anodised aluminium) equipped with glass exposure tubes
- Exposure chamber volume: 3L
- Method of holding animals in test chamber: restraint tubes which were positioned radially around the exposure chamber
- Source and rate of air: filtered air from a compressor; 0.5-1.0 L/min through each inhalation tube
- System of generating particulates/aerosols: Nebulizer
- Method of particle size determination: Mean Mass Median Aerodynamic Diameter (MMAD) of particle size distribution during exposure was calculated from two gravimetric measurements
- Temperature, humidity, pressure in air chamber: temperature and relative humidity of the test atmosphere in the exposure chamber was maintained as required by experimental conditions. Air flow was monitored regularly.
TEST ATMOSPHERE
- Brief description of analytical method used:
1. The test item usage determined once per exposure by weighing the amount of the test item before/after exposure to determine the quantity of test item used;
2. Aerosol concentration was determined by gravimetric analysis at least once during each hour of exposure. Test aerosol samples were collected onto a Whatman filter (grade F319-04) using a filter sampling device;
3. Particle size distribution was determined gravimetrically twice during exposure;
4. Temperature and relative humidity in the chamber was measured continuously during exposure; and
5. Actual air flow rate monitored hourly in each group during exposure.
- Samples taken from breathing zone: Not specified; but the exposure system ensured a uniform distribution
CLASS METHOD (if applicable)
- Rationale for the selection of the starting concentration: Several tests were performed to establish the highest stable aerosol concentration achievable that could be maintained at least for 4 hours. Aerosol starting dose of 5 mg/L air was selected as no toxic effects were expected based on the available data. - Analytical verification of test atmosphere concentrations:
- yes
- Duration of exposure:
- ca. 4 h
- Remarks on duration:
- 4 consecutive hours
- Concentrations:
- mean concentration of 5.0 mg/L air during 4 hours
- No. of animals per sex per dose:
- 3 males and 3 females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Examined daily for mortality and morbidity. Clinical observations made hourly during exposure and immediately and 1hr following exposure then once daily thereafter for remainder of observation period. Weights were taken just before the start of the inhalation period, daily from days 2 to 5, then on days 8, 10, 11 and immediately before sacrifice on day 15 of study.
- Necropsy of survivors performed: Yes
- Other examinations performed: clinical signs, body weight,organ weights, histopathology, other: clinical signs, body weight, post-mortem gross necropsy of abdominal and thoracic cavities and contents. Special attention paid to any change in respiratory tract - Key result
- Sex:
- not specified
- Dose descriptor:
- LC50
- Effect level:
- > 5 mg/L air (nominal)
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Mortality:
- All animals survived the scheduled observation period.
- Clinical signs:
- other: Transient clinical signs of toxicity (reduced mobility, absence of turning reflex, weakness, respiratory crackles)
- Body weight:
- Body weight stagnation in both sexes, but with a longer duration in females
- Gross pathology:
- No macroscopic findings were observed during necropsy.
- Other findings:
- Dirty fur was observed in all animals 1 hour after exposure. In addition, chromodacryorrhea (1 out of 3 males) and mild piloerection (1 out o 3 males and 2 out of 3 females) were recorded 1 hour after exposure. Chromodacryorrhea was not longer observed from day 2 of study onwards but dirty fur (all females) and mild piloerection (1 out o 3 males and 2 out of 3 females) were still present at day 2 of study. These clinical signs were not longer present at day 3 of study
- Interpretation of results:
- GHS criteria not met
- Remarks:
- according to EC 1278/2008 as amended
- Conclusions:
- LC50 of 1,3,5-Triisopropylbenzene was greater than 5.0 mg/L air (gravimetrically determined mean aerosol concentration).
- Executive summary:
The acute inhalation toxicity of 1,3,5-triisopropylbenzene was tested according to the acute toxic class method with Sprague-Dawley rats according to OECD TG 436. Treatment of animals with 1,3,5-triisopropylbenzene aerosol resulted in no deaths. However, a toxic effect was observed. This toxic effect was characterized by transient clinical signs of toxicity (reduced mobility, absence of turning reflex, weakness, respiratory crackles) and body weight stagnation in both sexes, but with a longer duration in females.
It was concluded that, under the experimental conditions:
LC50 of 1,3,5-Triisopropylbenzene was greater than 5.0 mg/L air (gravimetrically determined mean aerosol concentration).
Reference
3 deviations from the study plan were reported:
(1) Geometric Standard Deviation (GSD) on the two PSD determinations (PSD #1 and PSD #2) were 4.3 and 5.4 respectively, which are above the target range (1.5 to 3). Single outliers during weighing may have contributed to these high values. These values were considered to be acceptable taking into account that more than 89% and 67% of particles were below upper limit of 4µm in PSD #1 and PSD #2 respectively. These incidents are considered to have no impact on the quality / integrity of the study.
(2) Relative humidity and temperature in the husbandry room were sporadically below the optimal ranges during the study. This incident is considered not to have any impact on the quality/integrity of the study, since the relative humidity and temperature decreases were minor and no related clinical signs were recorded due to this incident.
(3) Coefficient of variation (%CV) in the high level of the exposure chamber was 6.17 %, which is slightly above the acceptance criteria (5%). Nevertheless, this incident is considered not to have an impact on the quality / integrity of the study, since all air flow values were in the range of 0.8-1.0 L/min which is within the airflow range required for inhalation studies to guarantee sufficient air flow supply to the animals during the exposure (0.5-1.0 L/min).
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 5 000 mg/m³ air
- Quality of whole database:
- The database is robust given the number and type of studies available, and consistency of findings.
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Mar 03 to May 12, 2015
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Version / remarks:
- 1987
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: Batch No. 6F11027000
- Expiration date of the lot/batch: 17. Nov. 2016
- Purity: 96% - Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Toxi-Coop Zrt. 1103 Budapest, Cserkesz u. 90
- Females nulliparous and non-pregnant: Yes
- Age at study initiation: young adult rats
- Weight at study initiation: Range in preliminary study = 203 – 237 g. Range in main study = 203-211 g (males) and 230-251 g (females)
- Housing: Type II polypropylene/polycarbonate; rat type cages with a solid floor, stainless steel wire covers and self- feeding baskets. During acclimatization: 3 animals/sex/cage. During the study: animals were housed individually.
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 5 days in preliminary study. 19 days at females, 5 days at males in main study
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 °C
- Humidity (%): 30 - 70 %
- Air changes (per hr): 10-15 air exchanges/hour by central air-condition system
- Photoperiod (hrs dark / hrs light): Artificial light, from 6 a.m. to 6 p.m. - Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: back, shaven
- % coverage: 10% of area of total body surface
- Type of wrap if used: sterile gauze pads and semi occlusive plastic wrap
REMOVAL OF TEST SUBSTANCE
- Washing: residual test item was removed using body temperature water.
- Time after start of exposure: 24 hr - Duration of exposure:
- 24 hrs
- Doses:
- Preliminary Study: 2000 mg/kg, 300 mg/kg, 50 mg/kg, 5 mg/kg (all but 2000 mg/kg dose where in a vehicle of sunflower oil)
Main Study: 2000 mg/kg (no vehicle) - No. of animals per sex per dose:
- Preliminary study: 2 females/dose
Main study: 5 males and 5 females - Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days for main study; 7 days for preliminary study
- Frequency of observations and weighing: morbidity/mortality observations made twice daily at the beginning and end of the working day. Clinical observation was made at the following intervals: 1h, 5h after the treatment and once each day for 14 days thereafter. Body weight was recorded on day 0 (shortly before the treatment), on day 7 and on day 15 in main study.
- Necropsy of survivors performed: Yes
- Other examinations performed: clinical signs, body weight,organ weights, histopathology, other: Observations included the skin and fur, eyes and mucous membranes, respiratory, circulatory, autonomic and central nervous system, somatomotor activity and behaviour pattern. Particular attention was directed to the observation of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma. All necropsied rats were examined for external appearance. The cranial, thoracic and abdominal cavities were opened and the appearance of the tissues and organs was observed, and any abnormality was recorded with details of its location, colour, shape and size. - Preliminary study:
- There were no deaths in preliminary study at 5, 50, 300 and 2000 mg/kg bw dose levels. Based on results of preliminary study, a limit test was performed on a dose of 2000 mg/kg bw.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality occurred after the 24-hour dermal exposure in male and female rats during the study
- Clinical signs:
- other: No behavioural changes, symptoms of dermal irritation and corrosion or signs of systemic toxity were noted during the study
- Gross pathology:
- No pathological changes were found related to the effect of the test item during the macroscopic examination of animals.
Internal necropsy finding as pale kidneys was detected in one male animal (No.: 4228) and in two female animals (No.: 3944, 3947). This alteration could not be related to the test item toxic effect, but was regarded an individual variation. Most likely the observation is a congenital anomaly.
Moderate hydrometra was found in female No.: 3931. The hydrometra is physiological finding and connected to the cycle of the animal. - Interpretation of results:
- GHS criteria not met
- Remarks:
- according to EC 1272/2008 as amended
- Conclusions:
- Under our experimental conditions, the acute dermal LD50 value of the test item 1,3,5-Triisopropylbenzene proved to be greater than 2000 mg/kg bw in male and female Crl:(WI)BR rats.
- Executive summary:
The acute dermal toxicity of 1,3,5-triisopropylbenzen was tested according to the standard acute method with Wistar rats according to OECD TG 402. A limit test was carried out. A single group of male and female animals (n=5 animals/sex) was exposed at 2000 mg/kg bw by dermal route. The test item was applied in original form and left in contact with the skin for 24 hours, followed by a 14-day observation period.
Neither male nor female animals treated at 2000 mg/kg bw showed behavioural changes and no systemic toxic signs were noted during the study.
The test item did not cause dermal irritation symptoms as erythema or oedema during 14-day observation period.
The body weight development was undisturbed in all animals.
No macroscopic alterations of organs referred to the systemic toxic effect of the test item were seen during the necropsy.
Under our experimental conditions, the acute dermal LD50 value of the test item 1,3,5-Triisopropylbenzene proved to be greater than 2000 mg/kg bw in male and female Crl:(WI)BR rats.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- The database is robust given the number and type of studies available, and consistency of findings.
Additional information
Justification for classification or non-classification
Acute Toxicity:
The acute oral LD50 is > 2000 mg/kg bw. Therefore, according to EC 1272/2008 as amended, the test substance does not meet the criteria for acute toxicity (oral) classification.
The acute inhalation 4h-LC50 is >5.0 mg/L. Therefore, according to EC 1272/2008 as amended, the test substance does not meet the criteria for acute toxicity (inhalation) classification.
The acute dermal LD50 is > 2000 mg/kg bw. Therefore, according to EC 1272/2008 as amended, the test substance does not meet the criteria for acute toxicity (dermal) classification.
Specific target organ toxicity – single exposure
No significant health effects which impaired function were reported in the available acute toxicity studies. Therefore, according to EC 1272/2008 as amended, the test substance does not meet the criteria for specific target organ toxicity – single exposure classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.